Grown Rogue International (GRUSF) Income towards Parent Company (2009 - 2026)
Grown Rogue International (GRUSF) posted quarterly Income towards Parent Company of -$2.2 million for Q1 2026, down 320.16% year-over-year from $1.0 million in Q1 2025, and up 100.0% quarter-over-quarter from -$6493.3 billion in Q4 2025.
Grown Rogue International (GRUSF) Income towards Parent Company (2009 - 2026) Analysis & Trends
Grown Rogue International's Income towards Parent Company history runs 18 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 320.16% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$3795.0 billion (down 375.25% YoY), while the FY2025 annual figure was -$2.1 million, up 81.27% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$2.2 million, up from -$6493.3 billion in the prior quarter.
- The five-year high for Income towards Parent Company was $2698.3 billion in Q3 2025, with the low at -$6493.3 billion in Q4 2025.
- The 5-year median for Income towards Parent Company is -$4989.0 (2022), against an average of -$328.1 billion.
- The sharpest annual moves came in 2025 and 2026: Income towards Parent Company jumped 437.92% in 2025, then tumbled 320.16% in 2026.
- Grown Rogue International's Income towards Parent Company stood at -$422824.0 in 2022, then soared by 252.03% to $642820.0 in 2023, then sank by 124220877.2% to -$798.5 billion in 2024, then tumbled by 713.17% to -$6493.3 billion in 2025, then soared by 100.0% to -$2.2 million in 2026.
- Business Quant data shows GRUSF's Income towards Parent Company at -$2.2 million in Q1 2026, -$6493.3 billion in Q4 2025, and $2698.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Grown Rogue International | 116.22 Mn | 104.68 Mn | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Mn |
| Mar 31, 2026 | -2.21 Mn |
| Dec 31, 2025 | -6,493.31 Bn |
| Sep 30, 2025 | 2,698.31 Bn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Sep 30, 2024 | -798.52 Bn |
| Jun 30, 2024 | -5.62 Mn |
| Mar 31, 2024 | -4.20 Mn |
| Dec 31, 2023 | 642,820.00 |
| Oct 31, 2023 | -1.47 Mn |
| Jul 31, 2023 | 640,713.00 |
| Apr 30, 2023 | 412,846.00 |
| Jan 31, 2023 | 931,945.00 |
| Jan 31, 2022 | -422,824.00 |
| Jul 31, 2021 | -54,533.00 |
| Apr 30, 2021 | -1.43 Mn |
| Jan 31, 2021 | -1.08 Mn |
| Oct 31, 2020 | 26,352.00 |
| Jul 31, 2020 | -798,200.00 |